Incyte Corp (INCY) 54.39 $INCY
Incyte Earnings Review: 11 Days after Announcement Shares Up 4.1% (INCY)
Comtex SmarTrend(R) - Mon May 12, 12:13PM CDT
A week ago on May 1st, 2014 Incyte (NASDAQ:INCY) reported earnings and analysts, on average, expected a loss of $0.17 on sales of $97.1 million. The company actually reported a loss of $0.21 per share on sales of $89.8 million, missing EPS estimates by $0.04 and missing revenue estimates by $7.3 million. Shares of Incyte have climbed from $50.05 to $52.08, representing a gain of 4.1% since the company reported earnings 11 days ago.
Global Market for Jak and Pi3k Therapy/Inhibitors to Reach $2.2 Billion in 2018; Tofacitinib Moving At 70.9% CAGR
PRWeb - Thu May 08, 8:47AM CDT
BCC Research (http://www.bccresearch.com) reveals in its new report, JAK AND PI3K SIGNALING PATHWAY MARKETS ,the global market for signal transduction therapies/inhibitors (JAK and PI3K) is expected to grow to $2.2 billion by 2018, with a five-year compound annual growth rate (CAGR) of 36.8%. Tofacitinib, the fastest growing segment, is expected to register a phenomenal CAGR of 70.9%
Earnings Releases, Dividends Announcements, and Product Improvements - Analyst Notes on Express Scripts, Humana, Endo, Incyte and Citrix
PR Newswire - Thu May 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Express Scripts Holding Company (NASDAQ: ESRX), Humana Inc. (NYSE: HUM), Endo International Plc (NASDAQ: ENDP), Incyte Corporation (NASDAQ: INCY) and Citrix Systems, Inc. (NASDAQ: CTXS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2197-100free.
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Technical Data on Biotech Stocks -- Research on Exact Sciences, Amgen, Exelixis, and Incyte
PR Newswire - Tue May 06, 8:57AM CDT
On Monday, May 05, 2014, the NASDAQ Composite ended at 4,138.06, up 0.34%, the Dow Jones Industrial Average finished the day 0.11% higher at 16,530.55, and the S&P 500 closed at 1,884.66, up 0.19%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 672.57, up 0.56%, and the index has advanced 0.12% in the last one month. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), Amgen Inc (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL) and Incyte Corp. Ltd (NASDAQ: INCY). Free technical research on EXAS, AMGN, EXEL and INCY can be downloaded upon signing up at:
3 Biotech Stocks Making Big Moves Last Week
Todd Campbell, The Motley Fool - Motley Fool - Mon May 05, 5:30PM CDT
Biotech investors have been taken on a roller coaster ride over the past few months as stratospheric gains in the fourth and first quarters have been realized to pay tax bills and rebalance to other industries. While Foolish investors should never...
After Yesterday's Rally of 3.62% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 05, 4:46PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $50.65 to a high of $53.91. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $52.64 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Incyte Rises 3.62% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 05, 4:46PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $50.65 to a high of $53.91. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $52.64 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Wider-than-Expected Q1 Loss at Incyte - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 10:00AM CDT
Incyte's (INCY) loss of 21 cents per share in the first quarter of 2014 was wider than the Zacks Consensus Estimate of a loss of 19 cents.
Incyte to Present at Upcoming Investor Conferences
Business Wire - Fri May 02, 7:00AM CDT
Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of May:
Why You Should Watch Merrimack, Exact Sciences, and Incyte Today
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:10AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Exact Sciences , Incyte Corporation and Merrimack Pharmaceuticals . Exact Sciences misses on earnings and revenue Exact Sciences posted a wider loss...
Incyte Reports 2014 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Business Wire - Thu May 01, 6:01AM CDT
--Positive top-line results from Phase III study of ruxolitinib in patients with polycythemia vera keep sNDA filing on track for second quarter 2014
After Yesterday's Rally of 7.83% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Apr 29, 6:00PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $45.17 to a high of $49.34. Yesterday, the shares gained 7.8%, which took the trading range above the 3-day high of $48.14 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Incyte After 7.83% Gain
Comtex SmarTrend(R) - Tue Apr 29, 5:59PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $45.17 to a high of $49.34. Yesterday, the shares gained 7.8%, which took the trading range above the 3-day high of $48.14 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
Incyte Down 26.2% Since SmarTrend Downtrend Call (INCY)
Comtex SmarTrend(R) - Mon Apr 28, 5:05PM CDT
SmarTrend identified a Downtrend for Incyte (NASDAQ:INCY) on March 21st, 2014 at $61.13. In approximately 1 month, Incyte has returned 26.25% as of today's recent price of $45.08.
Upcoming Conference Calls, Commencement of Shipments, Stock Price Movements, Awareness Campaigns, and Acquisitions - Analyst Notes on Incyte, Impax, ANI, Ironwood and Aastrom
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), Impax Laboratories Inc. (NASDAQ: IPXL), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) and Aastrom Biosciences, Inc. (NASDAQ: ASTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1519-100free.
Merck, P&G and Other Dividend Stocks You Wish You'd Bought in 2013
at The Street - Thu Apr 24, 5:00AM CDT
I've covered these dividend winners before, but you're not too late to get on board.
Global Peripheral T-Cell Lymphomas (PTCL) Therapeutics Pipeline Review 2014 - Analysis of 12 Companies & 22 Drug Profiles
M2 - Wed Apr 23, 8:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6sbss/peripheral_tcell) has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - ZIOPHARM Oncology, Inc. - Millennium Pharmaceuticals, Inc. - Eisai Co., Ltd. - Celgene Corporation - Incyte Corporation - Topotarget A/S - Mundipharma International Limited - Spectrum Pharmaceuticals, Inc. - Chipscreen Biosciences Ltd - CerRx, Inc. - Rhizen Pharmaceuticals SA Drug Profiles - belinostat - mogamulizumab - pralatrexate - pralatrexate - romidepsin - alisertib - pralatrexate - romidepsin - HBI-8000 - belinostat - mogamulizumab - ruxolitinib phosphate - darinaparsin - romidepsin - fenretinide - forodesine hydrochloride - pralatrexate - darinaparsin - denileukin diftitox - alefacept - TGR-1202 - darinaparsin For more information visit http://www.researchandmarkets.com/research/m6...eral_tcell
Incyte Earnings Review: 11 Days after Announcement Shares Up 4.1% (INCY)
Comtex SmarTrend(R) - Mon May 12, 12:13PM CDT
A week ago on May 1st, 2014 Incyte (NASDAQ:INCY) reported earnings and analysts, on average, expected a loss of $0.17 on sales of $97.1 million. The company actually reported a loss of $0.21 per share on sales of $89.8 million, missing EPS estimates by $0.04 and missing revenue estimates by $7.3 million. Shares of Incyte have climbed from $50.05 to $52.08, representing a gain of 4.1% since the company reported earnings 11 days ago.
Global Market for Jak and Pi3k Therapy/Inhibitors to Reach $2.2 Billion in 2018; Tofacitinib Moving At 70.9% CAGR
PRWeb - Thu May 08, 8:47AM CDT
BCC Research (http://www.bccresearch.com) reveals in its new report, JAK AND PI3K SIGNALING PATHWAY MARKETS ,the global market for signal transduction therapies/inhibitors (JAK and PI3K) is expected to grow to $2.2 billion by 2018, with a five-year compound annual growth rate (CAGR) of 36.8%. Tofacitinib, the fastest growing segment, is expected to register a phenomenal CAGR of 70.9%
Earnings Releases, Dividends Announcements, and Product Improvements - Analyst Notes on Express Scripts, Humana, Endo, Incyte and Citrix
PR Newswire - Thu May 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Express Scripts Holding Company (NASDAQ: ESRX), Humana Inc. (NYSE: HUM), Endo International Plc (NASDAQ: ENDP), Incyte Corporation (NASDAQ: INCY) and Citrix Systems, Inc. (NASDAQ: CTXS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2197-100free.
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Technical Data on Biotech Stocks -- Research on Exact Sciences, Amgen, Exelixis, and Incyte
PR Newswire - Tue May 06, 8:57AM CDT
On Monday, May 05, 2014, the NASDAQ Composite ended at 4,138.06, up 0.34%, the Dow Jones Industrial Average finished the day 0.11% higher at 16,530.55, and the S&P 500 closed at 1,884.66, up 0.19%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 672.57, up 0.56%, and the index has advanced 0.12% in the last one month. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), Amgen Inc (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL) and Incyte Corp. Ltd (NASDAQ: INCY). Free technical research on EXAS, AMGN, EXEL and INCY can be downloaded upon signing up at:
3 Biotech Stocks Making Big Moves Last Week
Todd Campbell, The Motley Fool - Motley Fool - Mon May 05, 5:30PM CDT
Biotech investors have been taken on a roller coaster ride over the past few months as stratospheric gains in the fourth and first quarters have been realized to pay tax bills and rebalance to other industries. While Foolish investors should never...
After Yesterday's Rally of 3.62% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 05, 4:46PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $50.65 to a high of $53.91. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $52.64 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Incyte Rises 3.62% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 05, 4:46PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $50.65 to a high of $53.91. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $52.64 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Wider-than-Expected Q1 Loss at Incyte - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 10:00AM CDT
Incyte's (INCY) loss of 21 cents per share in the first quarter of 2014 was wider than the Zacks Consensus Estimate of a loss of 19 cents.
Incyte to Present at Upcoming Investor Conferences
Business Wire - Fri May 02, 7:00AM CDT
Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of May:
Why You Should Watch Merrimack, Exact Sciences, and Incyte Today
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:10AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Exact Sciences , Incyte Corporation and Merrimack Pharmaceuticals . Exact Sciences misses on earnings and revenue Exact Sciences posted a wider loss...
Incyte Reports 2014 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Business Wire - Thu May 01, 6:01AM CDT
--Positive top-line results from Phase III study of ruxolitinib in patients with polycythemia vera keep sNDA filing on track for second quarter 2014
After Yesterday's Rally of 7.83% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Apr 29, 6:00PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $45.17 to a high of $49.34. Yesterday, the shares gained 7.8%, which took the trading range above the 3-day high of $48.14 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Incyte After 7.83% Gain
Comtex SmarTrend(R) - Tue Apr 29, 5:59PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $45.17 to a high of $49.34. Yesterday, the shares gained 7.8%, which took the trading range above the 3-day high of $48.14 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
Incyte Down 26.2% Since SmarTrend Downtrend Call (INCY)
Comtex SmarTrend(R) - Mon Apr 28, 5:05PM CDT
SmarTrend identified a Downtrend for Incyte (NASDAQ:INCY) on March 21st, 2014 at $61.13. In approximately 1 month, Incyte has returned 26.25% as of today's recent price of $45.08.
Upcoming Conference Calls, Commencement of Shipments, Stock Price Movements, Awareness Campaigns, and Acquisitions - Analyst Notes on Incyte, Impax, ANI, Ironwood and Aastrom
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), Impax Laboratories Inc. (NASDAQ: IPXL), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) and Aastrom Biosciences, Inc. (NASDAQ: ASTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1519-100free.
Merck, P&G and Other Dividend Stocks You Wish You'd Bought in 2013
at The Street - Thu Apr 24, 5:00AM CDT
I've covered these dividend winners before, but you're not too late to get on board.
Global Peripheral T-Cell Lymphomas (PTCL) Therapeutics Pipeline Review 2014 - Analysis of 12 Companies & 22 Drug Profiles
M2 - Wed Apr 23, 8:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6sbss/peripheral_tcell) has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - ZIOPHARM Oncology, Inc. - Millennium Pharmaceuticals, Inc. - Eisai Co., Ltd. - Celgene Corporation - Incyte Corporation - Topotarget A/S - Mundipharma International Limited - Spectrum Pharmaceuticals, Inc. - Chipscreen Biosciences Ltd - CerRx, Inc. - Rhizen Pharmaceuticals SA Drug Profiles - belinostat - mogamulizumab - pralatrexate - pralatrexate - romidepsin - alisertib - pralatrexate - romidepsin - HBI-8000 - belinostat - mogamulizumab - ruxolitinib phosphate - darinaparsin - romidepsin - fenretinide - forodesine hydrochloride - pralatrexate - darinaparsin - denileukin diftitox - alefacept - TGR-1202 - darinaparsin For more information visit http://www.researchandmarkets.com/research/m6...eral_tcell
